InMode Earnings Call Transcripts
Fiscal Year 2026
-
Q1 growth was driven by new product launches, but gross margins declined due to higher costs and increased competition. The company is expanding its product portfolio and international presence, while ongoing clinical studies and regulatory submissions target future growth. Guidance for 2026 remains cautious.
-
Operations face ongoing disruptions in Israel, with manufacturing at 60% capacity and logistics strained. Over $600 million has been returned via buybacks, while M&A targets focus on complementary tech and Asia. Growth is expected to resume in 2027, supported by new products and organizational restructuring.
-
After two years of decline, expectations are for a flat top line in 2026, with organizational restructuring and new product launches aimed at supporting recovery. Margin pressures persist due to laser commoditization, but growth in new verticals and a focus on North America are key strategies.
Fiscal Year 2025
-
Q4 2025 revenue rose year-over-year, but full-year sales declined 6% amid industry softness. International sales grew, while gross margins and EPS declined due to product mix and new laser launches. 2026 is expected to be a stabilization year, with new products and strategic alternatives under review.
-
The company has expanded from aesthetics into wellness, with strong growth in women's health and ophthalmology products. Despite a market slowdown due to high interest rates, it maintains high margins and is investing in new laser platforms and international expansion.
-
Q3 2025 revenue reached $93.2 million, with strong consumables growth and expanding international sales. Gross margins declined due to tariffs, and net income fell year-over-year. Guidance for 2025 remains unchanged, with management cautious about 2026 amid macro uncertainties.
-
Aesthetic market demand remains soft but has stabilized, with financing and macro headwinds impacting sales. Product innovation and expansion into new markets, including ophthalmology and women's health, are expected to drive growth. International operations are rebounding, and 5–6% annual revenue growth is targeted.
-
Q2 results showed U.S. weakness offset by strong international growth, prompting a downward guidance revision. Product innovation continues, with new non-invasive and wellness platforms, while management and sales structures are being realigned. Capital deployment remains flexible, with ongoing tariff mitigation efforts.
-
Q2 2025 revenue grew year-over-year, but ongoing macroeconomic headwinds led to a guidance reduction for the full year. Non-invasive and OUS segments showed strength, while North America remained challenged. Strategic expansion and new product launches are expected to support future growth.
-
The company is navigating a global economic slowdown with flat revenue guidance for 2024 and adjusted profitability expectations due to tariffs and a weaker U.S. market. New product launches and R&D remain robust, with regulatory approvals targeted for late 2026. $508 million in share buybacks and a focus on operational improvements aim to position the company for renewed growth.
-
The company is navigating a challenging market with a 20% revenue decline in 2024, driven by U.S. headwinds and high interest rates, but international markets show resilience. Recent product launches target new indications, and significant stock buybacks continue, while management remains focused on innovation and global expansion.
-
Q1 2025 revenue fell 3% year-over-year amid macroeconomic headwinds, with U.S. sales declining and international markets, especially Europe, showing relative strength. Guidance for 2025 was maintained but may be revised if Q2 does not show seasonal improvement.
-
High interest rates and weak consumer confidence are dampening equipment sales and patient demand, with no near-term recovery expected. New product launches and platform enhancements are positioned for future growth, while financial guidance remains cautious and share repurchases continue aggressively.
-
High inflation and interest rates have slowed elective procedure demand and equipment sales, but continued investment in R&D and marketing positions the company for future growth. New product launches and a strategic focus on women's health and ophthalmology are expected to drive long-term expansion.
-
Consumer demand and provider investment remain flat amid ongoing economic uncertainty and high interest rates. New product launches focus on efficiency and bundling trends, while operational investments and a disciplined M&A approach position the company for future recovery.
Fiscal Year 2024
-
2024 saw a 20% revenue decline amid macroeconomic headwinds and lower demand, but gross margins remained industry-leading. Over $285 million was returned to shareholders, and new platforms were launched with more planned for 2025. Guidance anticipates stable revenue and margins.
-
Management highlighted resilience amid macro and geopolitical headwinds, maintaining profitability and R&D investment despite a challenging 2024. New platforms Ignite and OptimasMAX were launched, with further innovation and international expansion planned for 2025 and beyond.
-
The aesthetic market remains soft with stable but challenging conditions, driven by lower patient demand and tougher financing. Continued investment in R&D and sales, a capital-intensive model, and expansion into new medical segments position the company for future growth. International markets and cross-selling to new physician groups are key growth drivers.
-
Q3 2024 saw revenue and sales declines due to macroeconomic headwinds and reduced minimally invasive treatments, prompting a downward revision of full-year guidance. New platforms saw early adoption, while management changes and share repurchases were notable.
-
A new $100 million share repurchase was announced for 2024, with further capital allocation options including acquisitions and dividends. North American demand for aesthetic procedures has softened, but international growth and new product upgrades offer future potential. Revenue guidance for 2024 is $430–$445 million, with long-term growth targeted at $30–$40 million annually.
-
Aesthetic device leader is navigating a cyclical downturn with strong profitability, robust innovation, and expanding international growth. Despite a 24% drop in U.S. consumable sales, guidance remains confident for a stronger second half, with M&A as a capital priority.
-
Q2 2024 saw lower revenues and margins due to decreased U.S. demand and macroeconomic headwinds, prompting a reduction in full-year guidance. New product launches and FDA clearances offer growth potential, but risks from economic conditions, supply chain, and counterfeits persist.
-
Management highlighted a major product refresh cycle, strong IP and margins, and ongoing innovation in both aesthetics and medical applications. Despite macroeconomic headwinds and financing challenges, international growth remains robust, and capital allocation is focused on disciplined M&A and share buybacks.